Merck, J&J and Bristol Myers CEOs face drug-pricing grilling on Capitol Hill, but experts cite deeper problems under the radar

Lawmakers have emphasized gaps between U.S. list prices and overseas costs for a handful of drugs made by the three drugmakers.

Previous post Stock-market investors fear a megacap meltdown. Here’s what history says.
Next post Paxos and Chainlink power up PayPal’s PYUSD with price feed integration